Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2011

View Archived Issues

Genus Oncology's GO-203-2c enters phase I trial in solid tumors

Mutant EPO lacking erythropoietic activity protects against ischemic brain injury

Modified mRNA molecules could be alternatives to DNA-based therapies

Regulating adenosine signaling improves symptoms of sickle cell disease

Programmable bio-nano-chips offer rapid and low-cost biomarker analysis

Creatine kinase levels predict hemorrhagic transformation in patients receiving alteplase for stroke

BPX-101 shows promise in phase I/II trial in metastatic prostate cancer

Tibotec begins recruitment in phase III trials of HCV protease inhibitor TMC-435

Novel renin inhibitors discovered at sanofi-aventis

Roche patents new activators of glucokinase

New inhibitors claimed of cGMP-dependent 3',5'-cyclic phosphodiesterase

Amgen reviews highlights of fourth quarter 2010

Vitae Pharmaceuticals claims new 11-beta-HSD1 inhibitors

UCSD clears Stemedica's phase I/II trial of allogeneic stem cells for stroke

Eisai divulges novel beta-secretase 1 inhibitors

Micell Technologies enrolls first patient in DESSOLVE-II trial of MiStent DES

Spanish scientists identify novel phenalenones with cytotoxic effects

Merck Serono Europe withdraws MAA for Movectro

EMA's CHMP recommends approval of Hizentra

Conatus Pharma begins phase II trial of CTS-1027 in hepatitis C

BioDelivery Sciences on track with phase III trial of BEMA Buprenorphine in chronic pain

Apricus Bio and FDA discuss SPA for phase III PrevOnco trial

Cytos obtains E.U. funding to help develop vaccines against emerging viral diseases

Antisense Therapeutics begins final preparations for first clinical trial of ATL-1103

FDA approves Corifact for prophylactic treatment of congenital coagulation factor XIII deficiency

CHMP issues positive opinion on Novartis' Rasilamlo for high blood pressure

Intercell's JE vaccine enters pivotal phase II/III pediatric trial in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...